Morgans Senior Analyst Scott Power recaps the healthcare picks for and what to look out for across the current active opportunities.
Some of the companies Scott talks about are: Mach7 Technologies (ASX:M7T), Impedimed (ASX:IPD), Micro-X(ASX:MX1), and Neuron Pharmaceuticals (ASX:NEU).

Morgans Senior Analyst Scott Power recaps the healthcare picks for the week ending in 13, November 2020.

Some of the active opportunities Scott details are Mach7 Technologies (ASX:M7T), Impedimed (ASX:IPD), Micro-X (ASX:MX1), and Neuron Pharmaceuticals (ASX:NEU).

Morgans Analyst Iain Wilkie talks with ResApp (ASX:RAP) CEO, Tony Keating, on a number of recent partnership agreements.

Morgans Senior Analyst, Dr. Derek Jellinek, provides a comprehensive update on the Covid-19 Vaccine. Additionally, Derek breaks down the key stakeholders within the race, and how they are currently positioned.

Neuren Pharmaceuticals’ (ASX:NEU) Chief Executive Officer, Jon Pilcher, sits down with Senior Analyst Scott Power. In this piece, Jon outlines a number of upcoming value drivers for the company.

Morgans Senior Analyst Scott Power notes three upcoming catalysts for Volpara (ASX:VHT) which are likely to move the share price higher.

Morgans Analyst Iain Wilkie recaps the healthcare teams picks for 2020 and what to look out for across the current active opportunities.

Michelle Gallaher, CEO of Opyl Ltd (ASX:OPL) provides an update to the network on what the company does, operational update, a number of new clients, and a potential opportunity ahead.

Morgans analyst Iain Wilkie sat down with Leo Lee, CEO of ASX listed regenerative medicine player Regeneus (ASX:RGS). The two speak on its recent partnership deal for osteoarthritis in Japan and what it means for the company.

Morgans Senior Healthcare Analyst Scott Power highlights four key buys with the Healthcare sector – ResMed (ASX:RMD), Virtus Health (ASX:VRT), EBOS (ASX:EBO) and Nanosonics (ASX:NAN).